Regarding the relationship among AR level, HER2 and the immune microenvironment, van Rooijen et al. found that in patients with HER2+ metastatic breast cancer receiving trastuzumab treatment, the infiltration of tumor immune cells with low AR expression increased, while the infiltration of tumor immune cells with high AR expression decreased22. Here, ERBB2 is linked to neoplasm.